Capmatinib (Tabrecta®). HTA ID: 22049

Assessment Status Rapid Review complete
HTA ID 22049
Drug Capmatinib
Brand Tabrecta®
Indication Advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
Assessment Process
Rapid review commissioned 11/07/2022
Rapid review completed 10/08/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of capmatinib compared with the current standard of care.

The company has not submitted a HTA dossier to the NCPE; therefore the cost-effectiveness of the technology could not be proven.